itacitinib + ruxolitinib

Itacitinib + ruxolitinib is an **investigational oral combination therapy** of two small molecule Janus kinase (JAK) inhibitors: itacitinib (a selective JAK1 inhibitor) and ruxolitinib (a JAK1/JAK2 inhibitor). Both agents target the JAK-STAT signaling pathway central to cytokine signaling and hematologic malignancies. Itacitinib primarily inhibits JAK1-mediated pathways, while ruxolitinib blocks both JAK1 and JAK2, resulting in reduced cytokine signaling, suppression of inflammatory responses, and inhibition of abnormal myeloid cell proliferation. This combination has been studied in myelofibrosis and other hematologic disorders to assess whether combined JAK inhibition may be more effective or better tolerated than monotherapy[1][3][7].

Other names

itacitinib and ruxolitinib combination